Gemmer Asset Management LLC Intra Cellular Therapies, Inc. Transaction History

Gemmer Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$64.37 - $75.65 $128,740 - $151,300	-2,000 Reduced 33.33%	4,000 $276,000
Q2 2023 Jul 19, 2023	SELL	$54.67 - $66.44 $109,340 - $132,880	-2,000 Reduced 25.0%	6,000 $379,000
Q1 2023 Apr 17, 2023	SELL	$43.8 - $56.99 $109,500 - $142,475	-2,500 Reduced 23.81%	8,000 $433,000
Q1 2022 Apr 20, 2022	SELL	$38.74 - $62.09 $77,480 - $124,180	-2,000 Reduced 16.0%	10,500 $642,000
Q3 2020 Oct 21, 2020	SELL	$17.61 - $31.86 $17,610 - $31,860	-1,000 Reduced 7.41%	12,500 $321,000
Q2 2020 Jul 31, 2020	BUY	$14.35 - $26.64 $35,875 - $66,600	2,500 Added 22.73%	13,500 $347,000
Q3 2019 Oct 11, 2019	BUY	$7.47 - $14.03 $7,470 - $14,030	1,000 Added 10.0%	11,000 $82,000
Q3 2017 Oct 12, 2017	BUY	$10.77 - $22.1 $107,700 - $221,000	10,000	10,000 $158,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Gemmer Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Gemmer Asset Management LLC with notifications on news.